Clinical Trial Results: A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MK-6598 as monotherapy and with pembrolizumab in advanced solid tumors; results completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Solid Tumors

Drugs mentioned

• MK-6598
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced or Metastatic Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2026-07-15